Lisata Therapeutics (NASDAQ:LSTA) Trading Up 11.8%

Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTAGet Rating) were up 11.8% during mid-day trading on Thursday . The company traded as high as $3.66 and last traded at $3.58. Approximately 70,094 shares traded hands during trading, an increase of 206% from the average daily volume of 22,893 shares. The stock had previously closed at $3.20.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on LSTA shares. Brookline Capital Management reiterated a “buy” rating on shares of Lisata Therapeutics in a research report on Monday, October 3rd. HC Wainwright upped their price objective on shares of Lisata Therapeutics from $6.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 19th.

Lisata Therapeutics Price Performance

The business has a 50-day moving average of $3.23. The company has a market cap of $28.13 million, a price-to-earnings ratio of -0.29 and a beta of 1.04.

Lisata Therapeutics (NASDAQ:LSTAGet Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.58). On average, analysts anticipate that Lisata Therapeutics, Inc. will post -10.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new position in Lisata Therapeutics in the 3rd quarter valued at approximately $57,000. State Street Corp acquired a new position in Lisata Therapeutics in the 3rd quarter valued at approximately $66,000. BlackRock Inc. acquired a new position in Lisata Therapeutics in the 3rd quarter valued at approximately $263,000. Renaissance Technologies LLC acquired a new position in Lisata Therapeutics in the 3rd quarter valued at approximately $467,000. Finally, Vanguard Group Inc. acquired a new position in Lisata Therapeutics in the 3rd quarter valued at approximately $817,000. 6.00% of the stock is currently owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

(Get Rating)

Lisata Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

Read More

Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.